Revista da Sociedade Brasileira de Medicina Tropical · 2026
Safety of tuberculosis-preventive treatment in children aged under 5 years: A rapid review.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Uchimura Liza Yurie Teruya, Yonekura Tatiana, Quintans Jeane Roza, Figueiró Mabel Fernandes, Casado Karina Dos Santos, Alves Eduardo de Souza, Johansen Fernanda Dockhorn Costa, Pelissari Daniele Maria, Souza Nicole Menezes de
Аннотация
BACKGROUND: This study aimed to synthesize evidence on the safety of tuberculosis-preventive treatment (TPT) in children aged <5 years, including those with immunocompromising conditions.
METHODS: A rapid review was conducted using PubMed, Embase, Virtual Health Library, and the Cochrane Library, including systematic reviews and primary studies.
RESULTS: Five studies were included, assessing isoniazid-based regimens. Adverse events were mild and reversible, such as transient liver enzyme elevations and peripheral neuropathy. Severe hepatotoxicity was rare and primarily reported in children with Human Immunodeficiency Virus (HIV).
CONCLUSIONS: TPT appears generally safe in children aged <5 years; however, evidence remains limited for shorter regimens and immunocompromised populations.
METHODS: A rapid review was conducted using PubMed, Embase, Virtual Health Library, and the Cochrane Library, including systematic reviews and primary studies.
RESULTS: Five studies were included, assessing isoniazid-based regimens. Adverse events were mild and reversible, such as transient liver enzyme elevations and peripheral neuropathy. Severe hepatotoxicity was rare and primarily reported in children with Human Immunodeficiency Virus (HIV).
CONCLUSIONS: TPT appears generally safe in children aged <5 years; however, evidence remains limited for shorter regimens and immunocompromised populations.